COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs.
Jih-Jin TsaiLi-Teh LiuChun-Hong ChenLiang-Jen ChenShiow-Ing WangJames Cheng Chung WeiPublished in: RMD open (2023)
RA with JAKi users had a significant risk for hospitalisation, mortality or composite adverse outcomes, especially higher mortality among those without COVID-19 vaccination. COVID-19 vaccination should be encouraged in these target cohorts. When using JAKi for patients with RA, clinicians should be vigilant about these adverse outcomes to prevent their occurrence or detect them early for early intervention.
Keyphrases
- coronavirus disease
- sars cov
- rheumatoid arthritis
- cardiovascular events
- randomized controlled trial
- respiratory syndrome coronavirus
- risk assessment
- disease activity
- risk factors
- palliative care
- ankylosing spondylitis
- cardiovascular disease
- systemic lupus erythematosus
- coronary artery disease
- adipose tissue
- cancer therapy
- skeletal muscle
- idiopathic pulmonary fibrosis
- weight loss